Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 10 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the receipt of final approvals from the USFDA for Silodosin and Pregabalin capsules. Silodosin capsules are used to treat symptoms of an enlarged prostate, while Pregabalin capsules are indicated for nerve pain. The drugs will be manufactured at the company's facility in Ahmedabad, India. This filing serves to inform the exchange and investors about these significant regulatory approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases